Angel Adegbesan
Reporter at Bloomberg News
Stocks reporter @business. Alum at @newmarkjschool and @yorkcollegecuny
Articles
-
2 weeks ago |
bloomberg.com | Angel Adegbesan
The stock market’s recent wipeout has pushed a quarter of biotechnology stocks to trade below their cash holdings. That’s left bargain-hunters with a choice: Buy the dip or sit this one out. In the wake of the selloff, roughly 25% of the 263-member Nasdaq Biotechnology Index have market values that were less than their most recently reported cash holdings after President Donald Trump made good on his promise of a trade war. That’s up from about 19% at the end of February.
-
3 weeks ago |
news.bloombergtax.com | Angel Adegbesan
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
-
3 weeks ago |
news.bloombergtax.com | Angel Adegbesan
XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
-
3 weeks ago |
news.bloomberglaw.com | Angel Adegbesan
shares tumble as much as 5.6%, the most intraday since December, after the nursing home firm said it delaying the release of its annual 10-K report, citing an ongoing investigation by an audit committee.
-
3 weeks ago |
mercurynews.com | Angel Adegbesan
By Angel Adegbesan | BloombergSoleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by a genetic disorder. Shares of the Redwood City, California-based company climbed 38% — the biggest one-day gain since September 2023 — to their highest level in more than eight years.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 258
- Tweets
- 175
- DMs Open
- No
RT @srimtaylor: For my latest @business story, I dug into 450 pages of rider complaints sent to NJ Transit to illustrate a system plagued b…
RT @CristinNara: A flurry of deals at the start of the year sparked optimism for a biotech stock resurgence but a swing in sentiment at the…
Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics' shares skyrocketing, but the drug developer needs a partner — or a buyer - to get to the next level. https://t.co/TMORmudQfh via @business